Effective January 31, 2019, if an Original Medicare order requires an Advance Beneficiary Notice (ABN) but does not include one, the order will be placed on hold. Not all Original Medicare orders will require an ABN - learn more about when one may be required here.
- Cancer Type
- Sample Type
- Results Expected
What is FoundationOne Heme?
FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.
FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.
select introns profiled
- A single test that detects the four main classes of genomic alterations for hematologic cancers and sarcomas
- Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
- Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision making and clinical trial enrollment